Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

l need such as ALS. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.  For more information about Acthar, including important safety information, please visit www.acthar.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "intent," "may," "plans," "potential," "should," "substantial," "will," or "would" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Research and development risks, including risks associated with Questcor's work in the area of ALS;
  • Our reliance on Acthar for substantially all of our net sales and profits;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014  As ... is pleased to announce the addition of new ... Center. The Medical Devices Knowledge Center ... research in the healthcare industry. Users have access ... expert, Kalorama Information, published from 1998 to present ...
(Date:8/26/2014)... Scientific Corporation (Nasdaq: KEQU ) today reported ... Sales for the quarter were $30,534,000, as ... last year. Net earnings for the quarter were $1,234,000, ... earnings of $1,587,000, or $0.61 per diluted share, in ... sales and earnings in the first quarter last year ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6
... 15, 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiac ... quarter ended June 30, 2011. More details on the financial ... 10-Q, filed today with the Securities and Exchange Commission. ... a top 5 global pharmaceutical company for two Phase I ...
... 15, 2011 For the first time, the ... guidance clarifying how benefit-risk determinations are made during ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Released today, ... the regulatory pathway for high-risk medical devices. The ...
Cached Medicine Technology:NewCardio Announces Financial Results for Its 2011 Second Quarter 2NewCardio Announces Financial Results for Its 2011 Second Quarter 3NewCardio Announces Financial Results for Its 2011 Second Quarter 4NewCardio Announces Financial Results for Its 2011 Second Quarter 5NewCardio Announces Financial Results for Its 2011 Second Quarter 6NewCardio Announces Financial Results for Its 2011 Second Quarter 7NewCardio Announces Financial Results for Its 2011 Second Quarter 8FDA Proposes Guidelines That Clarify Benefit-Risk Determinations for Medical Devices 2
(Date:8/27/2014)... 27, 2014 According to a ... "Ablation Technologies Market (Applications: Cardiovascular, Gynecology, Pain Management, ... Microwave, Cryotherapy) - Global Industry Analysis, Size, Share, ... global ablation technologies market was valued at USD ... reach a market worth USD 10,611 million in ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Representatives with Recharge Retreats ... list of destinations for International Yoga Teacher Trainings. , ... that the company chose Italy due to the fact ... trainings since it's an easy flight for Canadians and ... from all over Europe, UK, Africa, and the Middle ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Maleic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 IQ ... supplements, today announced its continued support of the Cystic ... Formulations participated in a fundraising campaign led by TigerFitness.com ... of IQ Formulations’ sales were donated to the respected ... to a TigerFitness.com fundraiser to support Isla, a young ...
Breaking Medicine News(10 mins):Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2
... On Thursday, January 8, Rhode Island Hospital treated ... as NanoKnife. Damian Dupuy, MD, director of ablation services ... ablation treatment, performed the procedure -- the first time ... the United States. , NanoKnife is an image-guided device ...
... Protica, Inc., the makers of the first capsulized ... to its product line. Following the FDA approval ... made with the natural sweetener will hit the ... the compact 2.9 fluid ounce beverage utilizes Actinase(R). ...
... Ill. and BATESVILLE, Ind., Jan. 9 ,Recognizing the ... excellent care at the patient,s bedside, Joint Commission,Resources ... are collaborating to launch a Nurse,Safety Scholar-in-Residence program ... Joint Commission. Hill-Rom is a global medical technology ...
... perception, reality , , FRIDAY, Jan. 9 (HealthDay News) -- ... their child,s eating and exercise habits, a new study ... Journal of Nutrition Education and Behavior that ... exercised well, while those with older children did not. ...
... Two words strike fear in the hearts of men and ... through the shock of that diagnosis, suffered the grief and ... the opportunity of a lifetime. In his new book, "Life ... AuthorHouse -- http://www.authorhouse.com ), he provides a valuable roadmap ...
... Mach One Corporation,(Pink Sheets: MNCN), a biological solutions ... benefit to the agricultural and consumer,market, announced today that ... January 7, 2009 related to a proposed transaction with ... the outstanding shares,of the Seller. , ...
Cached Medicine News:Health News:Rhode Island Hospital first in US to treat kidney tumor with new device using electrical pulses 2Health News:Protica Launches All-Natural Protein Beverage, Proasis 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 2Health News:JCR, Hill-Rom Launch Nurse Safety Scholar-in-Residence Program 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Mach One Corporation Enters Letter of Intent to Acquire Ceres Organic Harvest, Inc. 2
... Series from Thermo delivers maximum ... your low-speed clinical applications. With ... system, user-friendly controls, and generous ... Series delivers solid performance for ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Chembio Diagnostic Systems, Inc.s SURE CHECK HIV 1 / 2, HIV 1/ 2 STAT-PAK and HIV 1/ 2 STAT-PAK Dipstick tests are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of anti...
When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your insulin pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the cloc...
Medicine Products: